Treatment of intracranial aneurysms with the Enterprise stent: A multicenter registry - Clinical article

J. Mocco, Kenneth V. Snyder, Felipe C. Albuquerque, Bernard R. Bendok, Alan S. Boulos, Jeffrey S. Carpenter, David J. Fiorella, Brian L. Hoh, Jay U. Howington, Brian T. Jankowitz, Kenneth M. Liebman, Ansaar T. Rai, Rafael Rodriguez-Mercado, Adnan H. Siddiqui, Erol Veznedaroglu, L. Nelson Hopkins, Elad I. Levy

Research output: Contribution to journalArticle

212 Scopus citations


Object. The development of self-expanding stents dedicated to intracranial use has significantly widened the applicability of endovascular therapy to many intracranial aneurysms that would otherwise have been untreatable by endovascular techniques. Recent Food and Drug Administration approval of the Enterprise Vascular Reconstruction Device and Delivery System (Cordis) has added a new option for self-expanding stent-assisted intracranial aneurysm coiling. Methods. The authors established a collaborative registry across multiple institutions to rapidly provide large-volume results regarding initial experience in using the Enterprise in real-world practice. Ten institutions (University at Buffalo, Thomas Jefferson University, University of Florida, Cleveland Clinic, Northwestern University, West Virginia University, University of Puerto Rico, Albany Medical Center Hospital, the Neurological Institute of Savannah, and the Barrow Neurological Institute) have provided consecutive data regarding their initial experience with the Enterprise. Results. In total, 141 patients (119 women) with 142 aneurysms underwent 143 attempted stent deployments. The use of Enterprise assistance with aneurysm coiling was associated with a 76% rate of ≥ 90% occlusion. An inability to navigate or deploy the stent was experienced in 3% of cases, as well as a 2% occurrence of inaccurate deployment. Procedural data demonstrated a 6% temporary morbidity, 2.8% permanent morbidity, and 2% mortality (0.8% unruptured, 12% ruptured). Conclusions. The authors report initial results of the largest series to date in using the Enterprise for intracranial aneurysm treatment. The Enterprise is associated with a high rate of successful navigation and low occurrence of inaccurate stent deployment. The overall morbidity and mortality rates were low; however, caution should be exercised when considering Enterprise deployment in patients with subarachnoid hemorrhage as the authors' experience demonstrated a high rate of associated hemorrhagic complications leading to death.

Original languageEnglish (US)
Pages (from-to)35-39
Number of pages5
JournalJournal of neurosurgery
Issue number1
StatePublished - Jan 1 2009


  • Enterprise self-expanding stent
  • Intracranial aneurysm
  • Stent-assisted coiling

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Treatment of intracranial aneurysms with the Enterprise stent: A multicenter registry - Clinical article'. Together they form a unique fingerprint.

  • Cite this

    Mocco, J., Snyder, K. V., Albuquerque, F. C., Bendok, B. R., Boulos, A. S., Carpenter, J. S., Fiorella, D. J., Hoh, B. L., Howington, J. U., Jankowitz, B. T., Liebman, K. M., Rai, A. T., Rodriguez-Mercado, R., Siddiqui, A. H., Veznedaroglu, E., Hopkins, L. N., & Levy, E. I. (2009). Treatment of intracranial aneurysms with the Enterprise stent: A multicenter registry - Clinical article. Journal of neurosurgery, 110(1), 35-39.